Celltrion Healthcare, "Entering Top 10 in Turkey Prescription Market"

CELLTRION Healthcare announced on the 20th that it ranked among the top 10 companies in the hospital sales sector in T?rkiye (Turkey) last year, according to pharmaceutical market research firm IQVIA.

Exterior view of the Celltrion Healthcare headquarters building
[Photo by Celltrion Healthcare]

원본보기 아이콘

CELLTRION Healthcare attributed this achievement not only to product competitiveness but also to the sales capabilities and expertise of its local subsidiary led by Mahmut Dincer Uyar, the head of commercial operations. Starting with 'Remsima' (generic name infliximab) in 2017, CELLTRION Healthcare established a direct sales (direct-to-hospital) distribution network through its local subsidiary in T?rkiye and successfully stabilized this direct sales system, continuing to expand Remsima prescriptions. As the preference among local medical professionals steadily increased, Remsima recorded a market share of 51% in T?rkiye last year, surpassing the original drug 'Remicade' according to IQVIA.

Not only Remsima but also the oncology product line, which is directly prescribed in hospitals, has shown even more remarkable results. The market share of the oncology antibody biosimilar 'Herzuma' (generic name trastuzumab), launched in 2021, has rapidly grown despite being in its early stages. In the third quarter of last year, Herzuma succeeded in winning bids from the central government (DMO), which accounts for about 50% of the trastuzumab market in T?rkiye, leading to a market share of 71% last year. Additionally, 'Truxima' (generic name rituximab) maintained its position as the top prescribed drug in the market with a 76% share during the same period. CELLTRION Healthcare stated, "In T?rkiye's bid-centered pharmaceutical market, the flexible pricing policies of the local subsidiary and effective marketing strategies accelerated the increase in product market shares."

Model of Celltrion Healthcare's 'Remsima SC'.
Photo by Lee Chunhee

원본보기 아이콘

Based on this direct sales experience, CELLTRION Healthcare plans to continue launching follow-up products to further strengthen its market dominance. Starting next year with the subcutaneous (SC) formulation 'RemsimaSC,' new products such as 'Yuflyma' (generic name adalimumab) and 'Vegzelma' (generic name bevacizumab) will be introduced annually in T?rkiye. Especially when follow-up products are launched, the diversified product portfolio will enable the establishment of various strategies such as bundle sales, which is expected to enhance market competitiveness.

Kang Seok-hoon, head of CELLTRION Healthcare’s T?rkiye subsidiary, said, “With the easing of the COVID-19 pandemic and the recovery of hospital prescriptions, we have achieved the remarkable feat of ranking among the top 10 companies in hospital sales in T?rkiye based on the commercial capabilities of our local subsidiary. This year, we will continue to strengthen our subsidiary’s capabilities to expand prescriptions in the bidding market and do our best to sustain growth in the T?rkiye market next year, when follow-up products will be launched, serving as a bridgehead connecting Europe, the Middle East, and Asia.”

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.